Delving into the Latest Updates on GATT Technologies BV with Synapse

Overview

This is a pre-market, prospective, randomized (1:1), multicenter, pivotal clinical investigation. The purpose of this investigation is to determine the clinical performance of GATT-Patch as compared with SURGICEL® Original for the management of minimal, mild, or moderate bleeding during minimally invasive liver and gallbladder surgery.

Start Date06 Oct 2023

Sponsor / Collaborator

GATT Technologies BV

NCT05385952 / CompletedNot Applicable

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery

This is a pre-market, prospective, randomized (2:1), multicenter, multi-national pivotal clinical investigation. The purpose of this investigation is to determine the clinical safety and performance of GATT-Patch as compared with TachoSil for the management of minimal, mild, or moderate bleeding during elective open liver surgery.

Start Date04 Aug 2022

Sponsor / Collaborator

GATT Technologies BV

[+1]

NL-OMON53880 / SuspendedNot Applicable

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery - Safety/efficacy of GATT-Patch vs TachoSil During Open Liver Surgery

Start Date25 Jul 2022

Sponsor / Collaborator

GATT Technologies BV

100 Clinical Results associated with GATT Technologies BV

Login to view more data

0 Patents (Medical) associated with GATT Technologies BV

Login to view more data

100 Deals associated with GATT Technologies BV

Login to view more data

100 Translational Medicine associated with GATT Technologies BV

Login to view more data